发明名称 |
17-hydroxyprogesterone ester containing oral compositions and related methods |
摘要 |
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. |
申请公布号 |
US9364547(B2) |
申请公布日期 |
2016.06.14 |
申请号 |
US201414261057 |
申请日期 |
2014.04.24 |
申请人 |
LIPOCINE INC. |
发明人 |
Giliyar Chandrashekar;Venkateshwaran Srinivasan;Chickmath Basawaraj;Nachaegari Satish Kumar;Chidambaram Nachiappan;Patel Mahesh V. |
分类号 |
A61K31/56;A61K47/44;A61K9/48;A61K9/00;A61K31/57;A61K9/20;A61K9/14;A61K9/16;A61K8/63;A61Q11/00;A61K47/10;A61K47/12;A61K47/14;A61K47/20;A61K47/22;A61K47/26;A61K47/32 |
主分类号 |
A61K31/56 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a pregnant female subject at risk of preterm birth, said method comprising administering to the female subject a tablet or capsule oral pharmaceutical composition comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate with a mean particle diameter size of 50 micron or less and a pharmaceutically acceptable carrier
wherein (a) said pharmaceutically acceptable carrier includes (i) a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof; or (ii) a lipophilic additive and (b) said pharmaceutical composition, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., releases at least 20 wt % of the 17-hydroxyprogesterone caproate at 60 minutes. |
地址 |
Salt Lake City UT US |